Controversial drug boosts Medeva
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Controversial drug boosts Medeva
Buoyant sales of Methylphenidate, Medeva's controversial attention deficit disorder treatment, and cost controls helped the company report a 23 per cent rise in pre-tax profits from pounds 64.2m to pounds 79.0m in the year to December. After a 16 per cent rise in earnings per share to 16.9p, a final dividend of 2.6p made a total of 4.0p for the year, up 21 per cent. Analysts broadly welcomed the figures but expressed some concern at the rate of decline of respiratory sales in the US. The 34 per cent rise in Methylphenidate sales was in line with expectations. Medeva also said it had secured European distribution rights for ML Laboratories' dry powder asthma inhaler.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments